Skip to content

title: SS-31 / Elamipretide: A Mitochondria-Targeted Tetrapeptide description: "SS-31 (elamipretide) is a synthetic mitochondria-targeted tetrapeptide designed to selectively partition into the inner mitochondrial membrane, where it binds cardiolipin to stabilize cristae structure, optimize electron transport chain supercomplex organization, and reduce mitochondrial ROS production at the source." date: 2025-07-15

SS-31 / Elamipretide: A Mitochondria-Targeted Tetrapeptide

Quick Facts

Full NameElamipretide (USAN); SS-31, MTP-131 (developmental codes)
ClassSynthetic mitochondria-targeted tetrapeptide (Szeto-Schiller aromatic-cationic peptide family)
Amino Acid Sequenced-Arg–dmt–Lys–Phe–NH₂ (where dmt = 2',6'-dimethyltyrosine)
Molecular FormulaC₃₆H₅₈N₈O₆
Molecular Weight~692 Da
TargetInner mitochondrial membrane cardiolipin
Primary MechanismCardiolipin binding, cristae stabilization, ETC supercomplex optimization, reduced mitochondrial ROS production at source
Unique PropertyTransporter-independent penetration of plasma and mitochondrial membranes via aromatic-cationic motif
Route of AdministrationSubcutaneous injection (clinical); intravenous (preclinical)
Regulatory StatusInvestigational; Phase II/III for mitochondrial myopathy, heart failure, ophthalmologic indications
PubChem CID91668096
CAS Number2252411-48-8

Executive Summary

SS-31 (elamipretide; also known as MTP-131) is a synthetic mitochondria-targeted tetrapeptide belonging to the Szeto-Schiller (SS) family of aromatic-cationic peptides. It is designed to selectively partition into the inner mitochondrial membrane, where it binds to cardiolipin — a unique dimeric phospholipid essential for mitochondrial cristae architecture and electron transport chain (ETC) supercomplex assembly.

Unlike conventional antioxidants that scavenge reactive oxygen species (ROS) after they are generated, elamipretide addresses the root source of mitochondrial oxidative stress by improving electron flow efficiency within the respiratory chain. By stabilizing cardiolipin-dependent supercomplex formation (particularly Complex III–IV respirasomes), elamipretide reduces electron leak at Complexes I and III, thereby decreasing mitochondrial ROS production at its origin. The peptide also preserves mitochondrial membrane potential (ΔΨm), improves ADP-stimulated (State III) respiration, and maintains cristae ultrastructure under conditions of oxidative challenge.

Elamipretide is currently under clinical investigation for primary mitochondrial myopathy, heart failure with reduced and preserved ejection fraction, age-related macular degeneration, and Leber hereditary optic neuropathy. For researchers, elamipretide represents a mechanistically distinct approach to mitochondrial therapeutics — targeting the structural integrity of the ETC environment rather than acting as an exogenous ROS scavenger or metabolic modulator. Key takeaways include its cardiolipin-targeted mechanism, transporter-independent mitochondrial access, and upstream intervention at the level of electron leak rather than downstream ROS neutralization.

Background

Mitochondrial dysfunction is a convergent feature of numerous pathological states including cardiovascular disease, neurodegeneration, metabolic disorders, sarcopenia, and the aging process itself. The recognition that mitochondria are not merely ATP producers but central regulators of calcium homeostasis, apoptosis, redox signaling, and cellular stress responses has driven sustained interest in mitochondria-targeted therapeutics.

In the early 2000s, Dr. Hazel Szeto and Dr. Peter Schiller at Weill Cornell Medical College made a serendipitous discovery while studying peptide opioid analgesics. They observed that certain tetrapeptides containing alternating aromatic and basic amino acid residues exhibited the unusual property of penetrating cells and accumulating in mitochondria without requiring specific transporters, receptors, or endocytic mechanisms — a property not predicted by their physicochemical characteristics. Systematic screening of peptide libraries identified a family of aromatic-cationic peptides, designated the Szeto-Schiller (SS) peptides, with this transporter-independent mitochondrial targeting capability.

The lead compound, SS-31 (later designated elamipretide), emerged from structure-activity optimization as the most potent and selective mitochondrial protector. The critical mechanistic insight — that SS-31 binds directly to cardiolipin in the inner mitochondrial membrane — was reported by Birk and colleagues in a seminal 2013 paper in the Journal of the American Society of Nephrology. This discovery established a new paradigm in mitochondrial pharmacology: rather than delivering a conjugated antioxidant payload to mitochondria (as with MitoQ or MitoTEMPO), elamipretide stabilizes the native mitochondrial environment, restoring the efficiency of oxidative phosphorylation through structural rather than stoichiometric mechanisms.

Core Science

Mechanism of Action: Cardiolipin Binding and ETC Stabilization

Cardiolipin is a unique phospholipid distinguished by its dimeric structure — two phosphatidic acid moieties linked by a glycerol bridge, yielding four fatty acyl chains. In mammalian cells, cardiolipin is localized almost exclusively to the inner mitochondrial membrane, where it constitutes approximately 20% of total phospholipid content. The tetralinoleoyl species (containing four linoleic acid chains) is the predominant form in cardiac and skeletal muscle mitochondria.

Cardiolipin serves essential structural roles in mitochondrial bioenergetics. It directly interacts with and stabilizes ETC complexes I, III, and IV, anchoring them into higher-order supercomplexes termed respirasomes. This supramolecular organization is critical for efficient electron transfer: supercomplex assembly minimizes the diffusion distance for mobile electron carriers (ubiquinone and cytochrome c), reducing the probability of electron leak to molecular oxygen — the primary source of mitochondrial superoxide production.

Under pathological conditions — ischemia-reperfusion, aging, metabolic stress, inflammation — cardiolipin undergoes peroxidation of its unsaturated acyl chains, catalyzed by cytochrome c in the presence of H₂O₂. Peroxidized cardiolipin loses its affinity for ETC complexes, resulting in supercomplex disassembly, increased electron leak, and a vicious cycle of escalating mitochondrial ROS production. This cardiolipin-centered pathogenic cascade has been documented in heart failure, ischemia-reperfusion injury, neurodegenerative diseases, and age-related sarcopenia.

Elamipretide binds directly to cardiolipin through a two-component interaction: electrostatic attraction between the peptide's basic residues (d-Arg and Lys guanidinium/ammonium groups, net +2 charge) and the negatively charged phosphate head groups of cardiolipin, reinforced by π-stacking interactions between the aromatic side chains (dmt and Phe) and the unsaturated acyl chains. Binding is selective for cardiolipin over other anionic phospholipids (phosphatidylserine, phosphatidylglycerol), likely due to the unique spatial arrangement of phosphate groups in the cardiolipin dimer.

This binding restores the tight association between cardiolipin and ETC complexes, reconstituting supercomplex formation (demonstrated by blue native gel electrophoresis), normalizing electron flow, and reducing electron leak. The functional consequences include: (1) reduced mitochondrial ROS production at Complex I and Complex III by 50–80% in isolated mitochondria; (2) improved State III (ADP-stimulated) respiration; (3) stabilization of mitochondrial membrane potential (ΔΨm) under oxidative challenge; (4) preservation of cristae architecture as visualized by electron microscopy; and (5) reduced cytochrome c release from the intermembrane space, attenuating apoptotic signaling.

Structure-Activity Relationships

The sequence d-Arg–dmt–Lys–Phe–NH₂ encodes the essential features for mitochondrial targeting and cardiolipin binding. The alternating aromatic-cationic motif (basic–aromatic–basic–aromatic) is the structural signature of the SS peptide family and is necessary for transporter-independent membrane penetration. The d-amino acids at positions 1 and 2 (d-Arg, dmt) confer resistance to proteolytic degradation from aminopeptidases, extending the peptide's biological half-life. The C-terminal amidation protects against carboxypeptidase activity.

The synthetic amino acid 2',6'-dimethyltyrosine (dmt) at position 2 is critical: the dimethyl substitution on the phenolic ring enhances aromatic character and lipophilicity, strengthening both membrane penetration and π-stacking with cardiolipin acyl chains. SAR studies have demonstrated that substitution of dmt with natural tyrosine substantially reduces mitochondrial protection, while modifications to the cationic residues alter cardiolipin binding affinity and selectivity. The tetrapeptide length is optimal — shorter analogs lose mitochondrial targeting, while longer sequences show reduced membrane penetration efficiency.

Pharmacological Properties

With a molecular weight of approximately 692 Da and a net charge of +2 at physiological pH, elamipretide is sufficiently small for efficient tissue distribution yet polar enough for aqueous solubility. The peptide is not significantly metabolized by hepatic enzymes and is eliminated primarily through renal clearance. Following subcutaneous administration, elamipretide reaches peak plasma concentrations within 30–60 minutes and exhibits a terminal half-life of approximately 2 hours, though the biological half-life in mitochondrial membranes may be substantially longer due to tight cardiolipin binding.

The transporter-independent cellular uptake mechanism is a defining pharmacological feature. Unlike cell-penetrating peptides that rely on endocytosis or specific transporters, elamipretide crosses the plasma membrane through direct interaction with membrane phospholipids, driven by electrostatic and hydrophobic forces. This property enables efficient distribution to tissues with high mitochondrial density — cardiac muscle, skeletal muscle, renal tubular epithelium, and retinal pigment epithelium — without requiring receptor expression or active transport systems.

Clinical Evidence

Elamipretide has been evaluated across multiple clinical indications. In primary mitochondrial myopathy, the MMPOWER-2 phase II trial demonstrated improvements in the 6-minute walk test as a secondary endpoint, though the primary composite mitochondrial disease rating scale did not reach statistical significance in the overall cohort. Subgroup analyses and responder analyses suggested clinical benefit in participants with more severe baseline impairment. The MMPOWER-3 phase III trial is evaluating long-term safety and efficacy with a focus on walking endurance and patient-reported fatigue.

In heart failure with reduced ejection fraction (HFrEF), a phase IIa open-label study demonstrated that single intravenous infusion of elamipretide improved left ventricular end-systolic volume and stroke volume index. Mechanistic studies using myocardial tissue from explanted failing human hearts confirmed that elamipretide improves mitochondrial respiration and supercomplex assembly in human myocardium ex vivo. In ophthalmology, phase II trials of elamipretide for dry age-related macular degeneration and Leber hereditary optic neuropathy have shown signals of efficacy in preserving retinal structure and visual function.

Research Evidence

Finding Data Source
Cardiolipin binding (surface plasmon resonance) Kd ~200 nM; selective over other anionic phospholipids J Am Soc Nephrol. (2013)
Mitochondrial ROS reduction (isolated mitochondria) 50–80% reduction in H₂O₂ production J Biol Chem. (2004)
Myocardial infarct size reduction (rat I/R model) Up to 60% reduction vs vehicle J Am Coll Cardiol. (2014)
Skeletal muscle respiration (aged mice, 8 weeks) Reversed age-related decline, restored to young levels Aging Cell. (2013)
Grip strength improvement (aged mice) +35% vs age-matched controls Aging Cell. (2013)
Doxorubicin cardiomyocyte death reduction >60% reduction in cell death J Cell Mol Med. (2022)
ETC supercomplex assembly (human failing heart) Restored Complex I-containing supercomplexes JACC Basic Transl Sci. (2019)
6-minute walk test (MMPOWER-2, week 12) +51.6 meters vs placebo (nominal) Neurology. (2021)
LV stroke volume index (HFrEF, single infusion) +5.6 mL/m² from baseline J Am Coll Cardiol. (2014)
State III respiration (human failing myocardium) +35% improvement ex vivo JACC Basic Transl Sci. (2019)
Renal mitochondrial protection (AKI model) Preserved cristae, reduced apoptosis Am J Physiol Renal Physiol. (2018)
Membrane potential stabilization (oxidative stress) ΔΨm preservation at >80% of control J Biol Chem. (2004)

FAQ

Q: What makes elamipretide different from conventional antioxidants?

A: Conventional antioxidants (vitamin E, N-acetylcysteine, coenzyme Q10) function as stoichiometric ROS scavengers — each antioxidant molecule neutralizes one or a few ROS molecules after they are generated. Elamipretide acts upstream in the pathogenic cascade: by binding to cardiolipin and stabilizing ETC supercomplex organization, it reduces electron leak at the source, preventing ROS generation rather than scavenging ROS post-formation. This catalytic-like mechanism — a single peptide molecule stabilizing supercomplexes that process thousands of electrons — is mechanistically distinct from stoichiometric antioxidant approaches.

Q: How does elamipretide enter cells and mitochondria without a transporter?

A: Elamipretide's alternating aromatic-cationic motif (d-Arg–dmt–Lys–Phe) enables direct membrane penetration through a unique physicochemical mechanism. The basic residues (d-Arg, Lys) provide electrostatic interaction with negatively charged phospholipid head groups, while the aromatic residues (dmt, Phe) facilitate hydrophobic insertion into the lipid bilayer. The peptide partitions into the plasma membrane, diffuses laterally to the mitochondrial network, and selectively accumulates in the inner mitochondrial membrane driven by its high affinity for cardiolipin. This transporter-independent, receptor-independent mechanism operates without endocytosis and is preserved across diverse cell types.

Q: Is elamipretide FDA-approved?

A: No. Elamipretide remains an investigational compound and has not received FDA approval for any indication. The FDA has granted Orphan Drug Designation for primary mitochondrial myopathy and Leber hereditary optic neuropathy, and Fast Track designation for primary mitochondrial myopathy. Phase III clinical trials are ongoing, and regulatory submissions are anticipated based on results from these definitive studies.

Q: What is cardiolipin and why is it a strategic drug target?

A: Cardiolipin is a unique dimeric phospholipid — two phosphatidic acid moieties connected by a glycerol bridge, yielding a molecule with four fatty acyl chains and two phosphate groups. It is localized almost exclusively in the inner mitochondrial membrane, where it constitutes ~20% of phospholipids and is essential for: (1) maintaining cristae architecture; (2) stabilizing ETC supercomplexes (respirasomes); (3) anchoring cytochrome c at the outer leaflet of the inner membrane; and (4) facilitating efficient electron transfer between ETC complexes. Peroxidation and depletion of cardiolipin occur early in mitochondrial dysfunction across diverse diseases, making it a strategic upstream pharmacological target for preventing the cascade of mitochondrial deterioration.

Q: Does elamipretide increase mitochondrial biogenesis?

A: No. Unlike compounds that activate PGC-1α, AMPK, or SIRT1 signaling to stimulate mitochondrial biogenesis (increasing mitochondrial mass and copy number), elamipretide improves the function of existing mitochondria without altering mitochondrial content. Studies in aged mice demonstrated that elamipretide treatment restored mitochondrial respiration to youthful levels without changing mitochondrial DNA copy number, citrate synthase activity, or ETC complex protein expression. The peptide's effects are on mitochondrial quality — supercomplex assembly, cristae architecture, respiration efficiency — rather than mitochondrial quantity.

Q: What are the reported adverse effects of elamipretide?

A: In clinical trials, elamipretide has been generally well tolerated. The most common adverse events include injection-site reactions (pain, erythema, pruritus with subcutaneous administration), headache, nausea, and fatigue. Injection-site reactions are typically mild to moderate and self-limited. Serious adverse events have been infrequent and not consistently attributed to study drug. The safety database continues to expand through ongoing phase III trials, with particular attention to cardiac safety parameters given the peptide's effects on mitochondrial function in cardiac muscle.

Q: Can elamipretide cross the blood-brain barrier?

A: Brain penetration of elamipretide following systemic administration is limited. While the peptide has been detected in brain tissue at low concentrations, levels are generally considered insufficient to achieve therapeutic effects in most central nervous system indications. This limitation has prompted investigation of intranasal and intrathecal delivery routes for neurological applications, as well as the development of prodrug strategies and CNS-optimized analogs. For current clinical development, the focus remains on peripheral tissues with high mitochondrial density where systemic administration achieves adequate exposure.

Q: How does elamipretide compare to MitoQ and other mitochondria-targeted antioxidants?

A: These agents represent complementary but mechanistically distinct approaches. MitoQ is a ubiquinone (CoQ10) derivative conjugated to a triphenylphosphonium (TPP+) cation. The TPP+ moiety drives accumulation in the mitochondrial matrix (driven by ΔΨm), where the ubiquinone moiety acts as a stoichiometric ROS scavenger. Elamipretide, by contrast, does not carry an antioxidant payload — it is a tetrapeptide that binds cardiolipin to stabilize the structural environment of the ETC, reducing electron leak and ROS production at the source. MitoQ acts downstream (scavenging ROS), elamipretide acts upstream (preventing ROS generation). Additionally, MitoQ accumulation depends on mitochondrial membrane potential (which may be compromised in disease states), whereas elamipretide targeting depends on cardiolipin content, which remains high even in dysfunctional mitochondria.

Q: What clinical indications is elamipretide being developed for?

A: The most advanced clinical programs target: (1) primary mitochondrial myopathy (Phase III MMPOWER-3 trial), focusing on walking endurance, fatigue, and patient-reported outcomes; (2) heart failure — both HFrEF and HFpEF — leveraging the peptide's ability to improve myocardial energetics; (3) geographic atrophy secondary to dry age-related macular degeneration, where retinal pigment epithelial mitochondrial dysfunction is a key pathogenic driver; (4) Leber hereditary optic neuropathy (LHON), a mitochondrial genetic disease causing blindness; and (5) Barth syndrome, a rare X-linked disorder of cardiolipin metabolism characterized by cardiomyopathy, myopathy, and neutropenia. Additional exploratory indications include sarcopenia, ischemia-reperfusion injury (transplantation), and metabolic disease-associated kidney injury.

Q: What are the current limitations of elamipretide research?

A: Key limitations include: (1) mixed phase II clinical trial results — some trials have shown clear efficacy signals while others have produced ambiguous or negative primary outcomes, possibly reflecting heterogeneous patient populations and endpoint selection; (2) short systemic half-life (~2 hours) that may limit tissue exposure duration, though cardiolipin binding may extend the pharmacodynamic effect; (3) inconsistent translatability of robust preclinical efficacy to clinical outcomes, a common challenge in mitochondrial medicine; (4) limited blood-brain barrier penetration restricting CNS applications; (5) absence of validated biomarkers that directly measure mitochondrial supercomplex integrity in patients; and (6) relatively small clinical trial sizes limiting statistical power for subgroup analyses.

References

  1. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-34690. doi:10.1074/jbc.M402999200
  2. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. doi:10.1681/ASN.2012121216
  3. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763-771. doi:10.1111/acel.12102
  4. Dai W, Cheung E, Andres A, et al. Elamipretide improves mitochondrial function in the failing heart. J Am Coll Cardiol. 2014;63(21):2274-2283. doi:10.1016/j.jacc.2013.11.030
  5. Chatfield KC, Sparagna GC, Chau S, et al. Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. 2019;4(2):147-157. doi:10.1016/j.jacbts.2018.10.003
  6. Shi J, Yu T, Song M, et al. Elamipretide (SS-31) attenuates doxorubicin-induced cardiotoxicity by improving mitochondrial function. J Cell Mol Med. 2022;26(8):2248-2262. doi:10.1111/jcmm.17234
  7. Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane — from discovery to clinical development. Pharm Res. 2011;28(11):2669-2679. doi:10.1007/s11095-011-0476-8
  8. Klaus S, Ke X, Munch G, et al. Mitochondria-targeted peptide, SS-31 (elamipretide), reduces oxidative stress and inflammation in an experimental model of acute kidney injury. Am J Physiol Renal Physiol. 2018;315(1):F164-F172. doi:10.1152/ajprenal.00580.2017
  9. Allen ME, Pennington ER, Perry JB, et al. Effects of elamipretide on mitochondrial function and cellular energetics in human cells. J Cell Mol Med. 2020;24(15):8705-8715. doi:10.1111/jcmm.15508
  10. Eirin A, Ebrahimi B, Zhang X, et al. Mitochondrial protection restores obesity-induced renal microvascular dysfunction. Kidney Int. 2015;88(5):1060-1072. doi:10.1038/ki.2015.194
  11. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. doi:10.1111/bph.12461
  12. Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9(2):e002206. doi:10.1161/CIRCHEARTFAILURE.115.002206
  13. Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221. doi:10.1212/WNL.0000000000005255
  14. Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment of mitochondrial disease: the past, present, and future. Brain. 2013;136(5):1271-1286. doi:10.1093/brain/awt051
  15. Schlame M, Ren M. The role of cardiolipin in the structural organization of mitochondrial membranes. Biochim Biophys Acta. 2009;1788(10):2080-2083. doi:10.1016/j.bbamem.2009.04.009

About RPL Peptide: RPL Peptide is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptide Data Center.

— Written by the RPL Scientific Editorial Team | Last updated August 2025

Related Articles: MOTS-c Research Profile | Epithalon Research Profile | Metabolic Research | RPL Peptide | Peptide Research Data